Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity

Journal of Clinical Investigation

Volumn 100, Issue 5, 1997, Pages 1248-1255

  Brasoveanu, Lorelei I ^a   Fonsatti, Ester ^a   Visintin, Alberto ^a   Pavlovic, Mirjana ^a   Cattarossi, Ilaria ^a   Colizzi, Francesca ^a   Gasparollo, Aldo ^a   Coral, Sandra ^a   Horejsi, Vaclav ^b   Altomonte, Maresa ^a   Maio, Michele ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

GPI anchor; Immunotherapy; Malignant disease; PI PLC; Shedding

Indexed keywords

CD59 ANTIGEN; CELL MEMBRANE PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; MONOCLONAL ANTIBODY;

ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION;

EID: 0030885128     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119638     Document Type: Article

References (35)

1. Morgan, B.P., and S. Meri. 1994. Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15:369-396.
2. Davies, A., and P.J. Lachmann. 1993. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol. Res. 12: 258-275.
3. Lehto, T., and S. Meri. 1993. Interactions of soluble CD59 with the terminal complement complexes. J. Immunol. 151:4941-4949.
4. Davies, A., D.L. Simmons, G. Hale, R.A. Harrison, H. Tighe, P.J. Lachmann, and H. Waldmann. 1989. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170:637-654.
5. Meri, S., H. Waldmann, and P.J. Lachmann. 1991. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab. Invest. 65:532-536.
6. Telen, M.J., and W.F. Rosse. 1991. Phosphatidylinositol-glycan linked proteins of the erythrocyte membrane. Baillière's Clinical Haematalogy. 4:849-868.
7. Mäenpää A., S. Junnikkala, J. Hakulinen, T. Timonen, and S. Meri. 1996. Expression of complement membrane regulators membrane cofactor protein (CD46). decay accelerating factor (CD55). and protectin (CD59) in human malignant gliomas. Am. J. Pathol. 148:1139-1152.
8. Hakulinen, J., and S. Meri. 1994. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab. Invest. 71:820-827.
9. Bjørge, L., C.A. Vedeler, E. Ulvestad, and R. Matre. 1994. Expression and function of CD59 on colonic adenocarcinoma cells. Eur. J. Immunol. 24: 1597-1603.
10. Niehans, G.A., D.L. Cherwitz, N.A. Staley, D.J. Knapp, and A.P. Dalmasso. 1996. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149:129-142.
11. Brasoveanu, L.I., M. Altomonte, A. Gloghini, E. Fonsatti, S. Coral, A. Gasparollo, R. Montagner, I. Cattarossi, C. Simonelli, A. Cattelan, et al. 1995. Expression of protectin (CD59) in human melanoma and its functional role in cell-and complement-mediated cytotoxicity. Int. J. Cancer. 61:548-556.
12. Brasoveanu, L.I., M. Altomonte, E. Fonsatti, F. Colizzi, S. Coral, M.R. Nicotra, I. Cattarossi, A. Cattelan, P.G. Natali, and M. Maio. 1996. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab. Invest. 74:33-42.
13. Junnikkala, S., J. Hakulinen, and S. Meri. 1994. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur. J. Immunol. 24:611-615.
14. Rooney, I.A., and B.P. Morgan. 1992. Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology. 76:541-547.
15. Rooney, I.A., J.P. Atkinson, E.S. Krul, G. Schonfeld, K. Polakoski, J.E. Saffitz, and B.P. Morgan. 1993. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J. Exp. Med. 177:1409-1420.
16. Bjørge, L., T.S. Jensen, C.A. Vedeler, E. Ulvestad, E.K. Kristoffersen, and R. Matre. 1993. Soluble CD59 in pregnancy and infancy. Immunol. Lett. 36: 233-234.
17. Roddy, J., I. Clark, B.L. Hazleman, D.A.S. Compslon, and N.J. Scolding. 1994. Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders. J. Neurol. 241:557-560.
18. Altomonte, M., F. Colizzi, G. Esposito, and M. Maio. 1992. Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N. Engl. J. Med. 327:959.
19. Maio, M., B. Gulwani, J.A. Langer, R.S. Kerbel, G.J. Duigou, P.B. Fisher, and S. Ferrone. 1989. Modulation by interferons of HLA antigen, high-molecular-weight melanoma-associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. Cancer Res. 49:2980-2987.
20. Bernhard, H., K. Meyer zum Bhshenfelde, and W.G. Dippold. 1989. Gangliosides GD3 shedding by human malignant melanoma cells. Int. J. Cancer. 44:155-160.
21. Altomonte, M., A. Gloghini, G. Bertola, A. Gasparollo, A. Carbone, S. Ferrone, and M. Maio. 1993. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 53:3343-3348.
22. Becker, J.C., C. Termeer, R.E. Schmidt, and E.B. Bröcker. 1993. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J. Immunol. 151:7224-7232.
23. Puppo, F., M. Scudeletti, F. Indiveri, and S. Ferrone. 1995. Serum HLA class I antigens: markers and modulators of an immune response? Immunol. Today. 16:124-127.
24. Maio, M., and G. Parmiani. 1996. Melanoma immunotherapy: new dreams or solid hopes? Immunol. Today. 17:405-407.
25. Stefanova, I., I. Hilgert, H. Kristotova, R. Brown, M.G. Low, and V. Horejsi. 1989. Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol. Immunol. 26:153-161.
26. Houghton, A.N., D. Mintzer, C. Cordon-Cardo, S. Welt, B. Fliegel, S. Vadhan, E. Carswell, M.R. Melamed, H.F. Oettgen, and L.J. Old. 1985. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA. 82:1242-1246.
27. Maio, M., M. Altomonte, R. Tatake, R.A. Zeff, and S. Ferrone. 1991. Reduction in susceptibility to natural killer cell-mediated lysis of human F0-1 melanoma cells after induction of HLA-class-I antigen expression by transfection with B2m gene. J. Clin. Invest. 88:282-289.
28. 4. Nature (Lond.). 227:680-685.
29. Rodeck, U., A. Bossler, U. Graeven, F.E. Fox, P.C. Nowell, C. Knabbe, and C. Kari. 1994. Transforming growth factor β production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54:575-581.
30. Bjørge, L., T.S. Jensen, E.K. Kristoffersen, M. Ulstein, and R. Matre. 1996. Identification of the complement regulatory protein CD59 in human colostrum and milk. Am. J. Reprod. Immunol. 35:43-50.
31. Väkevä, A., M. Jauhiainen, C. Ehnholm, T. Leto, and S. Meri. 1994. High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma. Immunology. 82:28-33.
32. 2+-signaling competent. J. Cell Biol. 131:669-677.
33. Rooney, I.A., J.E. Heuser, and J.P. Atkinson. 1996. GPI anchored complement regulatory proteins in seminal plasma. J. Clin. Invest. 97:1675-1686.
34. Riethmüller, G., E. Schneider-Gädicke, and J.P. Johnson. 1993. Monoclonal antibodies in cancer therapy. Curr. Opin. Immunol. 5:732-739.
35. Brasoveanu, L.I., M. Altomonte, E. Fonsatti, S. Coral, A. Visintin, A. Cattelan, P.G. Natali, and M. Maio. 1996. Role of protectin (CD59) as regulator of complement-mediated lysis of melanoma cells: relevance in immunotherapy. In Immunology of Human Melanoma. Tumor-Host Interaction and Immunotherapy. M. Maio, editor. IOS Press, Ohmsa/Amsterdam/Tokyo/Washington, D.C. 185-194.